Chronic Kidney Disease - Pipeline Review, H1 2017
Chronic Kidney Disease - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 18, 1, 20 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 18, 1, 20 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) - Overview
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
Angion Biomedica Corp
apceth Biopharma GmbH
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BLR Bio LLC
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Cellmid Ltd
Chugai Pharmaceutical Co Ltd
Complexa Inc
Corvidia Corp
CTI BioPharma Corp
Evotec AG
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GNI Group Ltd
Lupin Ltd
Navya Biologicals Pvt Ltd
Nippon Zoki Pharmaceutical Co Ltd
Novartis AG
Otsuka Holdings Co Ltd
Prismic Pharmaceuticals Inc
Prolong Pharmaceuticals LLC
ProMetic Life Sciences Inc
Reata Pharmaceuticals Inc
Regulus Therapeutics Inc
Relypsa Inc
Resverlogix Corp
Spotlight Innovation Inc
Taisho Pharmaceutical Co Ltd
Toray Industries Inc
Tricida Inc
Unity Biotechnology Inc
Vascular BioSciences
VESSL Therapeutics Ltd
Vicore Pharma AB
Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles
(palmidrol + silibinin) - Drug Profile
ambrisentan - Drug Profile
ANG-3070 - Drug Profile
ANG-3281 - Drug Profile
ANG-3586 - Drug Profile
Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile
apabetalone - Drug Profile
AS-2444697 - Drug Profile
bardoxolone methyl - Drug Profile
BI-655088 - Drug Profile
BKE-001 - Drug Profile
BLR-400 - Drug Profile
C-21 - Drug Profile
CAB-101 - Drug Profile
calcium succinate - Drug Profile
CAR Peptide - Drug Profile
cardiotoxin - Drug Profile
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile
COR-001 - Drug Profile
CXA-10 - Drug Profile
dapagliflozin propanediol - Drug Profile
Drug for Kidney Diseases - Drug Profile
Drug to Activate sGC for Chronic Kidney Disease - Drug Profile
EOS-789 - Drug Profile
F-351 - Drug Profile
finerenone - Drug Profile
FM-1302 - Drug Profile
KBP-5074 - Drug Profile
LHW-090 - Drug Profile
MultiGeneGraft - Drug Profile
NAV-003 - Drug Profile
NZ-419 - Drug Profile
obinutuzumab - Drug Profile
pacritinib - Drug Profile
patiromer sorbitex calcium - Drug Profile
PBI-4050 - Drug Profile
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile
Sanguinate - Drug Profile
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile
Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease - Drug Profile
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile
Small Molecules for Chronic Kidney Disease - Drug Profile
Small Molecules for Chronic Kidney Disease - Drug Profile
SP-20103 - Drug Profile
SPR-494 - Drug Profile
Stem Cell Therapy for Chronic Kidney Disease - Drug Profile
Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
tesidolumab - Drug Profile
tolvaptan - Drug Profile
torsemide ER - Drug Profile
TRC-101 - Drug Profile
TS-143 - Drug Profile
verinurad - Drug Profile
Vida-5 - Drug Profile
VS-105 - Drug Profile
Wnt-001 - Drug Profile
YS-1402 - Drug Profile
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) - Overview
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
Angion Biomedica Corp
apceth Biopharma GmbH
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BLR Bio LLC
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Cellmid Ltd
Chugai Pharmaceutical Co Ltd
Complexa Inc
Corvidia Corp
CTI BioPharma Corp
Evotec AG
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GNI Group Ltd
Lupin Ltd
Navya Biologicals Pvt Ltd
Nippon Zoki Pharmaceutical Co Ltd
Novartis AG
Otsuka Holdings Co Ltd
Prismic Pharmaceuticals Inc
Prolong Pharmaceuticals LLC
ProMetic Life Sciences Inc
Reata Pharmaceuticals Inc
Regulus Therapeutics Inc
Relypsa Inc
Resverlogix Corp
Spotlight Innovation Inc
Taisho Pharmaceutical Co Ltd
Toray Industries Inc
Tricida Inc
Unity Biotechnology Inc
Vascular BioSciences
VESSL Therapeutics Ltd
Vicore Pharma AB
Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles
(palmidrol + silibinin) - Drug Profile
ambrisentan - Drug Profile
ANG-3070 - Drug Profile
ANG-3281 - Drug Profile
ANG-3586 - Drug Profile
Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile
apabetalone - Drug Profile
AS-2444697 - Drug Profile
bardoxolone methyl - Drug Profile
BI-655088 - Drug Profile
BKE-001 - Drug Profile
BLR-400 - Drug Profile
C-21 - Drug Profile
CAB-101 - Drug Profile
calcium succinate - Drug Profile
CAR Peptide - Drug Profile
cardiotoxin - Drug Profile
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile
COR-001 - Drug Profile
CXA-10 - Drug Profile
dapagliflozin propanediol - Drug Profile
Drug for Kidney Diseases - Drug Profile
Drug to Activate sGC for Chronic Kidney Disease - Drug Profile
EOS-789 - Drug Profile
F-351 - Drug Profile
finerenone - Drug Profile
FM-1302 - Drug Profile
KBP-5074 - Drug Profile
LHW-090 - Drug Profile
MultiGeneGraft - Drug Profile
NAV-003 - Drug Profile
NZ-419 - Drug Profile
obinutuzumab - Drug Profile
pacritinib - Drug Profile
patiromer sorbitex calcium - Drug Profile
PBI-4050 - Drug Profile
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile
Sanguinate - Drug Profile
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile
Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease - Drug Profile
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile
Small Molecules for Chronic Kidney Disease - Drug Profile
Small Molecules for Chronic Kidney Disease - Drug Profile
SP-20103 - Drug Profile
SPR-494 - Drug Profile
Stem Cell Therapy for Chronic Kidney Disease - Drug Profile
Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
tesidolumab - Drug Profile
tolvaptan - Drug Profile
torsemide ER - Drug Profile
TRC-101 - Drug Profile
TS-143 - Drug Profile
verinurad - Drug Profile
Vida-5 - Drug Profile
VS-105 - Drug Profile
Wnt-001 - Drug Profile
YS-1402 - Drug Profile
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BLR Bio LLC, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Regulus Therapeutics Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Relypsa Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Spotlight Innovation Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Tricida Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2017 (Contd.1), H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2017
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BLR Bio LLC, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Regulus Therapeutics Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Relypsa Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Spotlight Innovation Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Tricida Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2017 (Contd.1), H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2017
LIST OF FIGURES
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
COMPANIES MENTIONED
Angion Biomedica Corp
apceth Biopharma GmbH
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BLR Bio LLC
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Cellmid Ltd
Chugai Pharmaceutical Co Ltd
Complexa Inc
Corvidia Corp
CTI BioPharma Corp
Evotec AG
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GNI Group Ltd
Lupin Ltd
Navya Biologicals Pvt Ltd
Nippon Zoki Pharmaceutical Co Ltd
Novartis AG
Otsuka Holdings Co Ltd
Prismic Pharmaceuticals Inc
Prolong Pharmaceuticals LLC
ProMetic Life Sciences Inc
Reata Pharmaceuticals Inc
Regulus Therapeutics Inc
Relypsa Inc
Resverlogix Corp
Spotlight Innovation Inc
Taisho Pharmaceutical Co Ltd
Toray Industries Inc
Tricida Inc
Unity Biotechnology Inc
Vascular BioSciences
VESSL Therapeutics Ltd
Vicore Pharma AB
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
COMPANIES MENTIONED
Angion Biomedica Corp
apceth Biopharma GmbH
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BLR Bio LLC
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Cellmid Ltd
Chugai Pharmaceutical Co Ltd
Complexa Inc
Corvidia Corp
CTI BioPharma Corp
Evotec AG
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GNI Group Ltd
Lupin Ltd
Navya Biologicals Pvt Ltd
Nippon Zoki Pharmaceutical Co Ltd
Novartis AG
Otsuka Holdings Co Ltd
Prismic Pharmaceuticals Inc
Prolong Pharmaceuticals LLC
ProMetic Life Sciences Inc
Reata Pharmaceuticals Inc
Regulus Therapeutics Inc
Relypsa Inc
Resverlogix Corp
Spotlight Innovation Inc
Taisho Pharmaceutical Co Ltd
Toray Industries Inc
Tricida Inc
Unity Biotechnology Inc
Vascular BioSciences
VESSL Therapeutics Ltd
Vicore Pharma AB
